Navigation Links
Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
Date:11/3/2008

SAN DIEGO, Nov. 3 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced that it has initiated a Phase 2 clinical study with MP-376 for use as a maintenance therapy in reducing the incidence of pulmonary exacerbations in patients with chronic obstructive pulmonary disease (COPD). MP-376 is the company's novel formulation of levofloxacin inhalation solution.

The Phase 2, U.S. multi-center randomized, double-blind, placebo-controlled study (Mpex 302) is expected to enroll approximately 300 COPD patients to evaluate the safety, tolerability and efficacy of 5 days of dosing every 28 days, for up to 12 treatment cycles. Inclusion criteria are designed to enroll patients at high risk for acute exacerbations. The primary efficacy endpoint in this study is a comparison of the rate of acute exacerbations in patients treated with MP-376 versus placebo control. Additional endpoints will include the number, duration and severity of acute exacerbations, lung function, quality of life and functional status.

Chronic bacterial infection of the lower airways of patients with COPD results in inflammation that causes lung damage, as well as predisposes patients to acute exacerbations that arise from a variety of causes. Bacterial infections are a leading cause of these exacerbations and antibiotics are widely used to treat exacerbations when they occur. Although several bronchodilators and anti-inflammatory agents have been licensed for maintenance treatment, there are currently no inhaled antibiotics that are cleared for use in the U.S. for preventing the root cause of these exacerbations.

"There is significant enthusiasm in the clinical community for an inhaled antibiotic that can reduce the incidence of acute exacerbations in COPD in high risk patients," stated Dr. Jeff Loutit, Chief Medical Officer of Mpex Pharmaceuticals. "A therapy that addresses the underlying issues associated with COPD to reduce exacerbations would be highly beneficial and potentially result in slowing decline in lung function, improving quality of life, and reducing hospitalizations. We believe aerosol MP-376 is particularly well suited to confer such a benefit and we are eager to work with COPD physicians and patients to assess its potential in this indication."

Levofloxacin, the active ingredient in MP-376, has been shown in clinical studies to be active when given systemically against all of the common pathogens associated with bacterial exacerbations in COPD patients. By delivering the novel MP-376 formulation via the aerosol route, levofloxacin can be delivered directly to the lungs at much higher concentrations than can be achieved through usual oral and intravenous routes of administration. High concentrations are important to maximize bacterial killing and reduce the potential for development of drug resistance. Systemic exposures to levofloxacin are expected to be low when aerosol administration of MP-376 is used, potentially reducing the incidence of systemic side effects. MP-376 is also in clinical trials for potential use as a maintenance treatment in patients with cystic fibrosis.

About COPD

There are more than 9 million patients with COPD in the U.S. Approximately 10% of these patients are characterized as having severe disease which typically results in multiple acute exacerbations per year. These respiratory exacerbations are a major cause of disability, morbidity, mortality and healthcare expenditures. There is no cure for COPD and as such, current treatment is aimed at managing symptoms and preventing exacerbations.

About Mpex Pharmaceuticals

Mpex Pharmaceuticals is a clinical stage biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance. Mpex's most advanced product candidate, MP-376, is a proprietary aerosol formulation of levofloxacin that is being developed clinically as a maintenance therapy for the prevention of bacterial exacerbations in patients with cystic fibrosis and COPD. The company has also built a discovery and development platform and intellectual property estate around inhibitors of multi-drug resistant (MDR) efflux pumps (EPIs) found in many gram-negative bacterial pathogens. Bacterial efflux of antibiotics is a leading source of multi-drug resistance, particularly in gram-negative organisms. Mpex compounds have been shown in both in vitro and in vivo studies to overcome efflux-based resistance to multiple classes of antibiotics. Mpex recently entered into a collaboration with GlaxoSmithKline focused on developing multiple drug candidates utilizing Mpex's EPI technology. Company website: http://www.mpexpharma.com.


'/>"/>
SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
2. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
3. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
4. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
5. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
6. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
7. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
8. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
9. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
10. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
11. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 2016 Amarantus BioScience Holdings, Inc. ... for Regenerative Medicine, Neurology and Orphan Diseases, today announced that President ... two upcoming investor conferences: SeeThru Equity MicroCap Conference ... New York City , NY When: Tuesday, ... MicroCap Conference   Where: Grand Hyatt Hotel, 109 East ...
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
(Date:5/25/2016)... 25, 2016 According to a ... (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), ... (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to 2021", ... Animation Market for the forecast period of 2016 to ... Million by 2021 from USD 117.3 Million in 2016, ...
Breaking Medicine Technology:
(Date:5/28/2016)... Aliso Viejo, California (PRWEB) , ... May 28, 2016 , ... ... just need to drag and drop a preset onto their media," said Christina Austin ... from Pixel Film Studios, editors can quickly and easily add stylish color grades to ...
(Date:5/27/2016)... ... 27, 2016 , ... Southland Log Homes , designer and manufacturer of ... kits, which can be found on its website at SouthlandLogHomes.com. , The designs of ... they highlight the craftsmanship of timber post and beam construction. The result is ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, 2016 , ... ... the factors of a stroke, which we as a society can control and change. ... a stroke occurs nearly every 40 seconds within the United States. Plus, with an ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Aimed at ... human interest stories, which come courtesy of leaders in the nursing and health care ... from leading advocates and associations—namely Abilene Christian University. , As the nursing industry ...
(Date:5/26/2016)... Hampshire (PRWEB) , ... May 26, 2016 , ... ... care products, has been honored with a 2016 When Work Works Award for its ... award, part of the national When Work Works project administered by the Families and ...
Breaking Medicine News(10 mins):